Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.45 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.45 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.45 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.44 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.43 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10871690 | 1.00 | CHKA (0.50) | CHKAMEN1KMT2AHTTNR3C2 | |
| SCHEMBL22931682 | 0.97 | MEN1 (0.52) | CHKAMEN1KMT2AHTTNR3C2 | |
| SCHEMBL6567354 | 0.97 | MEN1 (0.52) | CHKAMEN1KMT2AHTTNR3C2 | |
| SCHEMBL31886 | 0.97 | MEN1 (0.52) | CHKAMEN1KMT2AHTTNR3C2 | |
| Benzene SCHEMBL14537401 | 0.97 | MEN1 (0.52) | CHKAMEN1KMT2AHTTNR3C2 | |
| SCHEMBL20385081 | 0.97 | MEN1 (0.52) | CHKAMEN1KMT2AHTTNR3C2 | |
| Water SCHEMBL10955435 | 0.93 | CHKA (0.50) | CHKAMEN1KMT2AHTTNR3C2 | |
| Iodide SCHEMBL28626203 | 0.93 | CHKA (0.50) | CHKAMEN1KMT2AHTTNR3C2 | |
| SCHEMBL7155149 | 0.93 | NR3C2 (0.56) | CHKAMEN1KMT2AHTTNR3C2 | |
| SCHEMBL6970154 | 0.93 | CHKA (0.50) | CHKAMEN1KMT2AHTTNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899205-A | Preparation method and application of single-site metal catalyst auxiliary agent | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119899204-A | Preparation method and application of borate compound | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-12391710-B2 | Method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-l-alanine | KOS THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-119899204-A | Preparation method and application of borate compound | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119899205-A | Preparation method and application of single-site metal catalyst auxiliary agent | 中国石油化工股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4073080-B1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230041504-A1 | METHOD FOR THE INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) METHYL)PROPANOYL)-L-ALANINE | KOS THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4073080-A1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | Pharmaleads (FR) | 2022-10-19 | — | — | EP | disclosed |
| CN-109311854-B | Benzazepine dicarboxamide compounds having secondary amide functionality | 豪夫迈·罗氏有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2021116617-A1 | PROCESS FOR INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL)METHYL)PROPANOYL)-L-ALANINE | PHARMALEADS (FR) | 2021-06-17 | — | — | WO | disclosed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-7345082-B2 | Phosphinic acids | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1685142-B1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1685142-A1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044830-A1 | PHOSPHINIC ACIDS DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107341-A1 | Phosphinic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| US-6518260-B1 | (α-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2003-02-11 | — | — | US | disclosed |
| US-6391866-B1 | ANALGESICS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-05-21 | — | — | US | disclosed |
| US-5300616-A | Process for isolating polyisocyanate isomers from polyisocyanate mixtures | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| EP-0550908-A2 | Process for the insulation of polyisocyanate isomers from poly-isocyanate mixtures | BAYER AG (DE) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041504-A1 | METHOD FOR THE INDUSTRIAL PREPARATION OF THE DISODIUM SALT OF ((2S)-3-([1,1'-BIPHENYL]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) METHYL)PROPANOYL)-L-ALANINE | CHAMP1, AADAT, PTMS | S1PR4 737/4885HSP90AA1 3124/4885S1PR1 244/4885 |
| US-12391710-B2 | Method for the industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-l-alanine | CHAMP1, PEAK1, AADAT | S1PR4 765/4885HSP90AA1 3058/4885S1PR1 275/4885 |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | S1PR4 1177/4885HSP90AA1 4454/4885S1PR1 1349/4885 |
| US-20050107341-A1 | Phosphinic acids | BACE1, PSEN1, PSEN2 | S1PR4 419/4885HSP90AA1 4180/4885S1PR1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.